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tA subpopulation of naive CD4 T cells that coex-
resses the interleukin (IL)–2 receptor  chain, CD25,
as been shown to have potent suppressor activity [1-12].
lthough they are present in both rodents and humans,
he frequencies of CD4CD25bright cells are higher in
odents than in humans (8%-12% versus 1%-3%, re-
pectively, of CD4 T cells). CD4CD25 cells have
een shown to play a vital role in the induction and
aintenance of peripheral self-tolerance by preventing
he proliferation and activation of autoreactive T cells
hat have escaped thymic deletion or that recognize ex-
rathymic antigens. Sakaguchi et al. [10] reported that
he transfer of CD4CD25 T cells into nude mice led
o the development of systemic autoimmune disorders
hat could be prevented by the co-transfer of
D4CD25 T cells. Others [2,3,9] showed that
D4CD25 T-cell transfer prevented autoimmunity
esulting from neonatal thymectomy and also inhibited
he development of autoimmune gastritis, intestinal in-
ammation, and autoimmune diabetes in diabetes-prone
nonobese diabetic) mice [1-4,9,13-19].
Fewer studies have addressed the role of
D425 cells in regulating in vivo alloresponses.
akaguchi et al. [10] found that nude mice rejected
llogeneic skin grafts faster if transferred lymphocytes
ere ﬁrst depleted of CD25 cells, thus indicating
hat CD25 cells suppress alloresponses. Our studies
ave shown that CD4CD25 cells regulate T-cell
lloresponses and tolerance induction [20]. Depletion
f CD425 cells augments a mixed lymphocyte re-
ction (MLR) culture. Adding a graded number of
D4CD25 T cells resulted in a dose-response re-
uction in alloproliferation. Co-stimulatory pathway
CD154:CD40 or CD28/CD152:B7 ligand) blockade
an induce tolerance to alloantigens in MLR cultures;
epletion of CD425 cells from the responder pop-
lation precludes tolerance induction, whereas add- i
6ack of cells restores tolerance induction; this reveals
n important role for CD425 cells in this form of
olerance induction.
With respect to the regulation of graft-versus-host
isease (GVHD) by in vivo infusion of CD425 cells,
everal laboratories (including ours) have shown that
D425 T cells present in the donor spleen graft
ownregulate GVHD lethality [21-28]. CD4CD25
ell depletion from the donor graft before in vivo infu-
ion resulted in accelerated GVHD morbidity and in-
reased mortality, thus indicating that CD4CD25
ells play a role in the regulation of GVHD [21,24,28].
his ﬁnding was observed in several strain combinations
rrespective of the conditioning regimen tested and re-
ardless of whether GVHD was mediated only by
D4 T cells or both CD4 and CD8 T cells [21].
his is consistent with the known suppressive effects of
D4CD25 T cells on CD8 T-cell responses. Sup-
lementation of the donor graft with donor but not host
D425 cells had a marked amelioration of GVHD
ethality in multiple strain combinations in multiple lab-
ratories [21-28]. Data fromThornton and Shevach [29]
ndicate that CD4CD25 cells became more potent
uppressor cells after activation and expansion with anti-
D3 monoclonal antibodies and IL-2. Therefore, it is
ot surprising that ex vivo activation and expansion of
D425 cells by exposure to reagents that induce
-cell receptor ligation and the presence of a high con-
entration of IL-2 resulted in signiﬁcant expansion of
his cell population and increased their anti-GVHD po-
ency [21,27], although a high degree of inhibition of
VHD lethality was observed in some studies with fresh
D425 cells [23]. Expansion of CD425 cells could
e achieved by exposure to anti-CD3 monoclonal anti-
odies or alloantigen-bearing antigen-presenting cells in
he presence of IL-2. In addition to the GVHD-inhib-
tory effects of donor CD425 cells, the presence of
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Regulatory T Cells
Bost CD4 or CD25 T cells at the time of allogeneic
onor lymphocyte administration also inhibited GVHD
ethality, thus indicating a role for endogenous
D425 cells in regulating the GVHD response. Al-
hough IL-10 production by donor CD4CD25 T
ells seems to contribute to the GVHD-inhibitory ca-
acity of these cells [23], elucidation of other mecha-
isms by which activated CD25 cells inhibit GVHD
emains unclear. The literature suggests several possibil-
ties that are not necessarily mutually exclusive. In vitro
uppression is dependent on cell-cell contact. Data from
akamura et al. [30] suggested that cell surface–bound
ransforming growth factor was responsible for the cell
ontact-dependent suppression, whereas Piccirillo’s
roup had disparate results [31]. Thornton and Shevach
8] showed that CD4CD25 T cells block IL-2 pro-
uction by CD4CD25 cells at the level of RNA tran-
cription. The relative IL-2 paucity could inhibit the
ctivation, proliferation, and effector function of both
D4CD25 and CD8 T cells. Other data indicate
hat CD152, glucocorticoid-induced tumor necrosis fac-
or receptor, or the transcription factor FoxP3 in
D4CD25 cells or the activation of CD4CD25
ells by the signaling of toll-like receptors both play an
mportant role in their regulatory function [19,32-39].
Of clinical signiﬁcance, 3 groups have shown that
D425 cells do not inhibit a graft-versus-leukemia
ffect [22,25,27]. Edinger et al. [22] demonstrated that
ytolytic T cell–mediated killing of 2 distinct B-cell leu-
emia/lymphoma cell lines was preserved despite inhibi-
ion of GVHD lethality by CD425 cell infusion.
ones et al. [27] showed that CD8 T cell–mediated
VHD was inhibited without precluding elimination of
cute myeloid leukemia cells if CD425 cells were
dministered 10 days after bone marrow transplantation.
renado et al. [25] demonstrated that ex vivo–expanded
D425 cells controlled GVHD but did not inhibit
limination of a B-cell leukemia/lymphoma cell line,
hereas the graft-versus-tumor response to a mastocy-
oma cell line was impaired. Collectively, these preclin-
cal data indicate that T-regulatory cells inhibit GVHD
nd bone marrow graft rejection but retain graft-versus-
eukemia/graft-versus-tumor effects.
CD425 T cells are heterogeneous in their
xpression of cell-surface antigens. For example,
pproximately two thirds of CD425 T cells in
ice express high levels of the lymph node (LN)
oming receptor, L-selectin (L-Sel; CD62L). Al-
hough both L-Selhi and L-SelloCD425 subsets
ave in vitro suppressor function [29], we hypoth-
sized that the L-Selhi T-regulatory cells would
ave superior therapeutic beneﬁt due to inhibition
f critical early GVHD priming events because of
heir ability to home to peripheral LNs via the
inding of the L-Sel molecule to determinants on
igh endothelial venules in these LNs. Initial hom-
ng of L-Selhi T-regulatory cells to the LNs would i
B&MTptimize the likelihood of interfering with the
riming and expansion of effector T cells, thereby
nhibiting an early phase of GVHD. Studies by
ohen et al. [24] used L-SelhiCD425 cells, but
omparisons with L-SelloCD425 cells were not
eported. Using whole body imaging, we have dem-
nstrated that L-SelhiCD425 cells reduced the
umbers of green ﬂuorescent protein–positive ef-
ector T cells in many types of tissues besides lym-
hoid organs [40]. Despite the presumed ability of
-SelloCD425 cells to migrate directly to sites of
nﬂammation, imaging data indicate little demon-
trable effect on the accumulation of green ﬂuores-
ent protein–positive T cells in GVHD target or-
ans in L-Sello–treated mice. Thus, optimization of
he homing and migration patterns of CD425
ells may be critical in achieving the most potent
nti-GVHD effects.
Because CD4CD25 cells are capable of sup-
ressing both CD4 and CD8 T cells [29], it is
easonable to assume that CD4CD25 cells may be
eneﬁcial in suppressing host antidonor responses that
an cause bone marrow graft rejection. This has now
een demonstrated by 3 separate groups using distinct
odel systems. Joffre et al. [41] showed that preacti-
ated CD425 cells prevented allogeneic bone mar-
ow graft rejection by host splenocytes given to le-
hally irradiated recipients. We have shown that
-Selhi but not L-Sello preactivated and expanded
D425 cells prevent bone marrow graft rejection
n sublethally irradiated recipients via a transforming
rowth factor –independent mechanism [40]. Ha-
ash and Levy [42] showed that the addition of donor
D425 cells resulted in greater lineage-committed
nd multipotential donor progenitors in recipient
pleens 1 week after transplantation and signiﬁcantly
ncreased long-term multilineage donor chimerism in
ublethally irradiated recipients.
A major limitation for the clinical application of
uman CD4CD25 cells has been their paucity in
eripheral blood. Only the CD425bright cells are po-
ent suppressors, and such cells are typically hypopro-
iferative [11]. Although exogenous IL-2 can support
uman CD4CD25 cell proliferation, the initial
rotocols published for human CD4CD25 T cells
esulted in limited expansion [5-7]. However, recent
ublications have solved this problem [43,44]. Studies
y Godfrey et al. [44] have used a non–cell sorter,
ead-based approach to isolate CD425hi cells from
dult peripheral blood mononuclear cells, which were
ble to be expanded 100-fold in 2 to 3 weeks. These
xpanded CD425 cells were far more potent sup-
ressors of MLR cultures than fresh cells and retained
he expression of L-Selhi and other LN homing
eceptors. Hoffmann et al. [43] have shown that
D425bright cells can be isolated by using cell-sort-ng approaches and that such isolated cells can be
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4xpanded in large numbers while still retaining ex-
ression of L-Selhi. Recent studies by Godfrey et al.
45] have shown that cord blood cell CD425 cells
re more readily isolated and more often lead to high
evels of suppression compared with adult peripheral
lood mononuclear cells. Thus, the stage is set for
linical trials of CD425 cells for GVHD inhibition
nd therapy and engraftment promotion.
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